Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma

The median survival time of patients with glioblastoma is 14-16 months with a 5-year overall survival rate of 9.8%. Standard of care treatment includes radiation with concomitant temozolomide followed by cyclic temozolomide. If the patient develops myelosuppression (thrombocytopenia, leukopenia or a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, K. Grace, Uhlmann, Erik N., Wong, Eric T., Uhlmann, Erik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549395/
https://www.ncbi.nlm.nih.gov/pubmed/33062270
http://dx.doi.org/10.3892/mco.2020.2150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549395/
https://www.ncbi.nlm.nih.gov/pubmed/33062270
http://dx.doi.org/10.3892/mco.2020.2150

Ejemplares similares